We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+34.63%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$208M
AUM Growth
-$246M
Cap. Flow
-$176M
Cap. Flow %
-84.46%
Top 10 Hldgs %
83.47%
Holding
151
New
27
Increased
12
Reduced
37
Closed
67

Top Buys

Rank Stock Value
1
HMTV
Hemisphere Media Group, Inc.
HMTV
+$9.46M
2
LOOP icon
Loop Industries
LOOP
+$2.38M
3
TRNX
Taronis Technologies, Inc. Common Stock
TRNX
+$1.52M
4
NVAX icon
Novavax
NVAX
+$1.36M
5
CODX
Co-Diagnostics
CODX
+$928K

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$37.5M
2
ESPR
Esperion Therapeutics
ESPR
+$6.39M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$4.97M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.47M
5
XERS icon
Xeris Biopharma Holdings
XERS
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 10.57%
2 Materials 0.95%
3 Consumer Discretionary 0.9%
4 Technology 0.61%
5 Industrials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKAO
76
PUT
DELISTED
Achaogen Inc
AKAO
$6K ﹤0.01%
+136
New +$143
PHIOW
77
DELISTED
Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021
PHIOW
$5K ﹤0.01%
194,959
– –
APDNW
78
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$4K ﹤0.01%
192,302
-409,760
-68% -$6.19K
CSCI
79
PUT
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
– –
0
– –
NSPRZ
80
DELISTED
InspireMD, Inc. Series B Warrants
NSPRZ
$1K ﹤0.01%
1,067,324
-364,809
-25% -$438
ALT icon
81
Altimmune
ALT
$581M
– –
-237,921
Closed -$709K
AMRN
82
Amarin Corp
AMRN
$293M
– –
-4,252
Closed -$1.53M
AMRN
83
PUT
Amarin Corp
AMRN
$293M
– –
-137
Closed -$3.74M
BNBX
84
DELISTED
BNB PLUS CORP
BNBX
– –
0
– –
ARMP icon
85
Armata Pharmaceuticals
ARMP
$174M
– –
-58,293
Closed -$168K
ATOS icon
86
Atossa Therapeutics
ATOS
$24.1M
– –
-33,497
Closed -$513K
AYTU icon
87
AYTU BioPharma
AYTU
$22.9M
– –
-2,575
Closed -$408K
AZN icon
88
CALL
AstraZeneca
AZN
$267B
– –
-743
Closed -$5.64M
AZN icon
89
PUT
AstraZeneca
AZN
$267B
– –
-1,656
Closed -$12.6M
CARM
90
PUT
DELISTED
Carisma Therapeutics
CARM
– –
-92
Closed -$260K
MBAI
91
Check-Cap
MBAI
$8.12M
– –
-849
Closed -$37K
CTXR icon
92
Citius Pharmaceuticals
CTXR
$13.7M
– –
-1,122
Closed -$29K
CVM icon
93
CEL-SCI Corp
CVM
$21M
– –
-1,075
Closed -$93K
DNTH icon
94
Dianthus Therapeutics
DNTH
$5.55B
– –
-6,697
Closed -$611K
DRRX
95
CALL
DELISTED
DURECT Corp
DRRX
– –
-55
Closed -$27K
DRRX
96
DELISTED
DURECT Corp
DRRX
– –
-13,190
Closed -$64K
ESPR
97
DELISTED
Esperion Therapeutics
ESPR
– –
-138,958
Closed -$6.39M
ESPR
98
PUT
DELISTED
Esperion Therapeutics
ESPR
– –
-8,467
Closed -$38.9M
IMNN icon
99
Imunon
IMNN
$6.43M
– –
-55
Closed -$22.8K
JAGX icon
100
Jaguar Health
JAGX
$4.74M
– –
0
– -$300K
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sabby Management held 151 positions worth $208M, down 54% from $455M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Sabby Management withdrew a net $176M in Q1 2019, closing 67 positions and reducing 37 holdings. Its most notable exit was Esperion Therapeutics, an estimated $6.39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 11% of assets, down from 21% a quarter earlier, followed by Materials and Consumer Discretionary.

Against the trend, Sabby Management opened a new position in Hemisphere Media Group, Inc. worth $113K.

  • Sabby Management's largest Q1 2019 buy was Hemisphere Media Group, Inc.: 708,417 shares worth $113K.
  • Sabby Management added most to OpGen, Inc in Q1 2019, an estimated $921K increase.
  • Sabby Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $37.5M.
  • Sabby Management fully exited Esperion Therapeutics in Q1 2019, selling an estimated $6.39M.
  • Sabby Management's ten largest holdings make up 83% of its $208M portfolio in Q1 2019.
  • Sabby Management opened 27 new positions and closed 67 in Q1 2019.
  • Sabby Management's portfolio value fell 54% quarter-over-quarter to $208M.

Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.